MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Update

MiNK Therapeutics, Inc. (NASDAQ:INKT) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 30,700 shares, an increase of 104.7% from the January 31st total of 15,000 shares. Based on an average daily volume of 31,600 shares, the short-interest ratio is currently 1.0 days. Approximately 3.1% of the company’s shares are sold short.

MiNK Therapeutics Trading Down 6.3 %

INKT stock traded down $0.57 during mid-day trading on Monday, hitting $8.39. 1,738 shares of the company were exchanged, compared to its average volume of 47,086. The company has a market capitalization of $33.23 million, a PE ratio of -2.15 and a beta of 0.17. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $19.00. The firm has a fifty day simple moving average of $8.63 and a 200 day simple moving average of $7.74.

Wall Street Analyst Weigh In

A number of research firms have recently commented on INKT. Robert W. Baird cut their price target on shares of MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. HC Wainwright raised their target price on MiNK Therapeutics from $9.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 25th.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.